Literature DB >> 12774849

Effects of cannabinoids on endogenous K+ and Ca2+ currents in HEK293 cells.

Clemente Vásquez1, Ricardo A Navarro-Polanco, Miguel Huerta, Xóchitl Trujillo, Felipa Andrade, Benjamín Trujillo-Hernández, Leonardo Hernández.   

Abstract

Effects of cannabinoids on endogenous potassium and calcium currents in HEK293 cells were studied using the whole-cell variant of the patch-clamp technique. The cannabinoid agonists WIN 55,212-2, methanandamide, and anandamide (1 microM) decreased the calcium current by 53.1 +/- 2.6, 47.5 +/- 1.2, and 38.8 +/- 3.1%, respectively, after transfection of human CB1 cannabinoid receptor (hCB1) cDNA into HEK293 cells. The delayed rectifier-like current was not changed after application of these agonists, but the inward rectifier was increased by 94.0 +/- 3.6, 83.7 +/- 5.1, and 63.0 +/- 2.5% after application of WIN 55,212-2, methanandamide, and anandamide, respectively. The effects of the cannabinoid antagonists (AM251, AM281, and AM630) on the inward rectifier and calcium currents were the opposite of those seen with cannabinoid agonists; thus, these compounds act as inverse agonists in this preparation. These results suggest that endogenous inward rectifier and calcium currents are modulated by cannabinoids in HEK293 cells, and that some expressed receptors may be constitutively active.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12774849     DOI: 10.1139/y03-055

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  13 in total

Review 1.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 2.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

3.  Cell type-specific regulation of inhibition via cannabinoid type 1 receptors in rat neocortex.

Authors:  Claire L De-May; Afia B Ali
Journal:  J Neurophysiol       Date:  2012-10-10       Impact factor: 2.714

4.  CB1 receptor-dependent desensitisation of TRPV1 channels contributes to the analgesic effect of dipyrone in sensitised primary sensory neurons.

Authors:  Gilson Goncalves Dos Santos; Ruihui Li; Melissa Pui Een Ng; Julia Borges Paes Lemes; Willians Fernando Vieira; Istvan Nagy; Cláudia Herrera Tambeli; Carlos Amilcar Parada
Journal:  Br J Pharmacol       Date:  2020-09-06       Impact factor: 8.739

5.  Genetically controlled upregulation of adenosine A(1) receptor expression enhances the survival of primary cortical neurons.

Authors:  Tsvetan Serchov; Hasan-Cem Atas; Claus Normann; Dietrich van Calker; Knut Biber
Journal:  Mol Neurobiol       Date:  2012-08-17       Impact factor: 5.590

6.  Effects of cannabinoids on tension induced by acetylcholine and choline in slow skeletal muscle fibers of the frog.

Authors:  Xóchitl Trujillo; Enrique Sánchez-Pastor; Felipa Andrade; Miguel Huerta
Journal:  J Membr Biol       Date:  2013-11-12       Impact factor: 1.843

7.  Endocannabinoids modulate encoding of sequential memory in the rat hippocampus.

Authors:  Sam A Deadwyler; Robert E Hampson
Journal:  Psychopharmacology (Berl)       Date:  2008-01-22       Impact factor: 4.530

8.  Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex.

Authors:  M Steffens; C Engler; J Zentner; T J Feuerstein
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

9.  Modulation of sensory neuron potassium conductances by anandamide indicates roles for metabolites.

Authors:  R M Evans; K N Wease; C J MacDonald; H A Khairy; R A Ross; R H Scott
Journal:  Br J Pharmacol       Date:  2008-03-31       Impact factor: 8.739

10.  Presynaptic cell dependent modulation of inhibition in cortical regions.

Authors:  Afia B Ali
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.